Literature DB >> 10572598

p53 and chemosensitivity.

C G Ferreira1, C Tolis, G Giaccone.   

Abstract

BACKGROUND: Although hematologic malignancies and some solid tumors such as germ cell tumors and pediatric malignancies can be cured by cytotoxic treatment, the most prevalent solid tumors are relatively resistant to these interventions. Apoptosis is involved in the cell kill of anticancer drugs and p53 is believed to be of principal importance in this process. However p53 also plays a role in cell cycle arrest and DNA repair, cellular processes that can decrease the sensitivity to chemotherapy. Therefore, p53 may play a dual role after exposure to cytotoxic treatment, activating either mechanisms that lead to apoptosis or launching processes directing to DNA repair and survival of the cell.
DESIGN: In this article, we review in details the p53 functions involved in the mediation of chemosensitivity. The preclinical and clinical data published in the recent years about the relation between p53 and chemosensitivity are discussed and the potential pitfalls associated to most of these studies, and that may account for the contradictory results produced so far are also mentioned.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572598     DOI: 10.1023/a:1008361818480

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  38 in total

Review 1.  Studies of apoptosis in breast cancer.

Authors:  M Parton; M Dowsett; I Smith
Journal:  BMJ       Date:  2001-06-23

2.  Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.

Authors:  Hsi-Hsien Hsu; Li-Hao Cheng; Tsung-Jung Ho; Wei-Wen Kuo; Yueh-Min Lin; Ming-Cheng Chen; Nien-Hung Lee; Fuu-Jen Tsai; Kun-Hsi Tsai; Chih-Yang Huang
Journal:  Tumour Biol       Date:  2013-08-30

3.  Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Authors:  Tongsen Zheng; Jiabei Wang; Xuan Song; Xianzhi Meng; Shangha Pan; Hongchi Jiang; Lianxin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

4.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

Authors:  Walter M Stadler; Seth P Lerner; Susan Groshen; John P Stein; Shan-Rong Shi; Derek Raghavan; David Esrig; Gary Steinberg; David Wood; Laurence Klotz; Craig Hall; Donald G Skinner; Richard J Cote
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

5.  Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B.

Authors:  Rebecca Hamm; Yoshikazu Sugimoto; Heinrich Steinmetz; Thomas Efferth
Journal:  Invest New Drugs       Date:  2014-07-29       Impact factor: 3.850

6.  The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer.

Authors:  Veronique F Cocquyt; Vera R Schelfhout; Phillip N Blondeel; Herman T Depypere; Kristof K Daems; Rudolphe F Serreyn; Marleen M Praet; Simon J P Van Belle
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

7.  Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

Authors:  Carmen Plasencia; Albert Abad; Eva Martinez-Balibrea; Miquel Taron
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 8.  Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

Authors:  Robert T Jones; Kenneth M Felsenstein; Dan Theodorescu
Journal:  Urol Clin North Am       Date:  2015-10-31       Impact factor: 2.241

9.  Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.

Authors:  Abdellah Mansouri; Qingxiu Zhang; Lon D Ridgway; Ling Tian; Francois-Xavier Claret
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

Review 10.  Pharmacogenomics in bladder cancer.

Authors:  Garrett M Dancik; Dan Theodorescu
Journal:  Urol Oncol       Date:  2014-01       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.